Face2Face Africa on MSN
‘This is rare!’ Elite athlete and breast cancer survivor shares story after shock diagnosis at 26
In October 2022, she discovered a small lump and sought medical attention. Despite her concerns, she was reassured that ...
The U.S. Food and Drug Administration (FDA) has granted priority review and breakthrough therapy designation to the ...
Daiichi Sankyo submits sNDA to Japan’s MHLW for Enhertu plus pertuzumab to treat patients with HER2 positive unresectable or recurrent breast cancer: Tokyo Wednesday, October 8, ...
Marty Willis' inspiring journey battling HER2-positive breast cancer during the pandemic highlights the importance of early ...
Bournemouth Daily Echo on MSN
'I'm so fortunate to be alive': Woman urges checks after cancer diagnosis
A woman is urging others to speak with their doctors after she was diagnosed with an aggressive breast cancer nearly 20 years ...
Trastuzumab deruxtecan (T-DXd) significantly improves IDFS over trastuzumab emtansine (T-DM1) in high-risk HER2-positive ...
LaShae Rolle is determined to spread awareness about the importance of early detection and the power of self-advocacy when it ...
Breast cancer recurrence occurs in about 20 to 30 percent of women within the first five to ten years after initial treatment ...
Renee Lesueur, a 61-year-old Billings woman, now has a new outlook on life after she spent the past year battling stage 2 ...
How to navigate an early-in-life breast cancer diagnosis, from fertility concerns to career questions: What the research ...
October is Breast Cancer Awareness Month, and CURE is here to address some of the most common questions patients have after a ...
Daiichi Sankyo & AstraZeneca’s sBLA for Enhertu followed by THP accepted in US for patients with high-risk HER2 positive early-stage breast cancer prior to surgery: Tokyo Friday ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback